Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
View Patent ↗A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.
1. A method for diagnosing a stroke, comprising:
a) analyzing a body fluid of a patient to detect the presence and concentration level of one or more ischemic markers selected from the group consisting of Growth Associated Protein 43, Glutamine Synthetase, Glial Fibrillary Acid Protein, Glycine Transporter 1, Glycine Transporter 2, Neuron Specific Glycoprotein, Calpain, Neurofibrillary Protein, Heat Shock Protein72, Beta Amyloid Precursor Protein, Calbindin D-28K, Proteolipid Protein, Myelin Associated Glycoprotein and Neurofilament H;
b) analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein; and
c) from the information obtained from said analyses, verifying the occurrence of stroke.
2. A method for the diagnosis of stroke comprising:
a) analyzing the body fluid of a patient to detect the presence and concentration level of one or more ischemic markers selected from the group of specific glial markers consisting of Growth Associated Protein 43, Glutamine Synthetase, Glial Fibrillary Acid Protein, Glycine Transporter 1, And Glycine Transporter 2;
b) analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein; and
c) from the information obtained from said analyses, verifying the occurrence of stroke.
3. A method for the diagnosis of stroke comprising:
a) analyzing the body fluid of a patient to detect the presence and concentration level of one or more ischemic markers selected from the group of specific neuronal markers consisting of Neuron Specific Glycoprotein, Calpain, Neurofibrillary Protein, Heat Shock protein 72, And Beta Amyloid Precursor Protein;
b) analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein; and
c) from the information obtained from said analyses, verifying the occurrence of stroke.
4. A method for the diagnosis of stroke comprising:
a) analyzing the body fluid of a patient to detect the presence and concentration level of one or more ischemic markers selected from the group of specific axonal markers consisting of, Calbindin D-28K, Proteolipid Protein, Myelin Associated Glycoprotein and Neurofilament H;
b) analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein; and
c) from the information obtained from said analyses, verifying the occurrence of stroke.
5. The method of any one of claims 1 , 3 and 4 , further including the step of determining the evolution and/or time of occurrence of said stroke or cerebral event.
6. A method as defined in claim 1 wherein said body fluid is selected from the group consisting of blood, products derived from blood, and cerebrospinal fluid.
7. A method as defined in claim 1 wherein said brain endothelial cell membrane protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, NeurothelinHT7, Gamma Glutamyl Transpeptidase, P-glycoprotein and combinations containing two or more of the endothelial cell membrane proteins.
8. A method as defined in claim 7 , wherein said brain endothelial cell membrane protein is Thrombomodulin.
9. A method as defined in claim 1 , wherein each of said analyses is carried out on the same sample of body fluid.
10. A method as defined in claim 1 , wherein at least-one of said analyses is carried out on a first sample of body fluid and at least another of said analyses is carried out on a second sample of body fluid, wherein said first and said second samples of body fluid are taken at the same or different time periods.
11. A method as defined in claim 1 , wherein at least one of said analyses comprises contacting said body fluid with an antibody which is specific for said marker.
12. A method as defined in claim 1 , wherein at least one of said analyses is carried out with an enzyme-labeled immunoassay.